Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial

Published:2004-02 Issue:3 Volume:77 Page:422-425
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:Transplantation

Author:

Wiland Anne M.,Fink Jeffrey C.,Weir Matthew R.,Philosophe Benjamin,Blahut Steven,Weir M. Ryan,Copenhaver Beth,Bartlett Stephen T.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference18 articles.

1. Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996

2. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors

3. DISPOSITION OF BASILIXIMAB, AN INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY, IN RECIPIENTS OF MISMATCHED CADAVER RENAL ALLOGRAFTS1

4. REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for living donor kidney transplantation;Nefrología (English Edition);2022-12

2. Recomendaciones para el trasplante renal de donante vivo;Nefrología;2022-04

3. Implication of interleukin-2 receptor antibody induction therapy in standard risk renal transplant in the tacrolimus era: a meta-analysis;Clinical Kidney Journal;2019-01-14

4. Renal Transplantation in Second-Level Private Hospitals in the State of Mexico;Transplantation Proceedings;2018-03

5. Post-Transplant Malignancy after Pediatric Kidney Transplantation: Retrospective Analysis of Incidence and Risk Factors in 884 Patients Receiving Transplants Between 1963 and 2015 at the University of Minnesota;Journal of the American College of Surgeons;2017-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3